• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CLPT

    ClearPoint Neuro Inc.

    Subscribe to $CLPT
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally invasive surgical procedures in the heart. It has license and collaboration agreements with The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Microsystems, LLC, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Irvine, California.

    IPO Year:

    Exchange: NASDAQ

    Website: clearpointneuro.com

    Recent Analyst Ratings for ClearPoint Neuro Inc.

    DatePrice TargetRatingAnalyst
    7/25/2024$10.00Buy
    B. Riley Securities
    10/24/2023$8.00Buy
    Stifel
    2/16/2023$14.00Buy
    B. Riley Securities
    4/5/2022$15.00Buy
    B. Riley Securities
    See more ratings

    ClearPoint Neuro Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fletcher R John was granted 486 shares, increasing direct ownership by 0.52% to 94,398 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      4/2/25 8:23:54 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Director Richards Timothy T. was granted 938 shares, increasing direct ownership by 1% to 66,288 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      4/2/25 8:22:36 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Director Girin Pascal E R was granted 525 shares, increasing direct ownership by 0.70% to 75,018 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      4/2/25 8:21:29 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Chief Operating Officer Sabra Mazin converted options into 13,050 shares and covered exercise/tax liability with 6,627 shares, increasing direct ownership by 14% to 51,203 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      3/14/25 4:45:48 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Chief Business Officer Stigall L. Jeremy converted options into 15,497 shares and covered exercise/tax liability with 5,545 shares, increasing direct ownership by 15% to 74,308 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      3/14/25 4:40:14 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer D'Alessandro Danilo converted options into 16,313 shares and covered exercise/tax liability with 8,284 shares, increasing direct ownership by 13% to 70,746 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      3/14/25 4:35:59 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • CEO and President Burnett Joseph Michael converted options into 42,414 shares and covered exercise/tax liability with 23,405 shares, increasing direct ownership by 7% to 290,132 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      3/14/25 4:33:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Chief Business Officer Stigall L. Jeremy converted options into 8,292 shares and covered exercise/tax liability with 2,967 shares, increasing direct ownership by 9% to 64,356 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      3/13/25 6:19:37 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer D'Alessandro Danilo converted options into 4,146 shares and covered exercise/tax liability with 2,106 shares, increasing direct ownership by 3% to 62,717 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      3/13/25 6:16:23 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Chief Business Officer Stigall L. Jeremy converted options into 17,777 shares and covered exercise/tax liability with 6,361 shares, increasing direct ownership by 24% to 59,031 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      3/10/25 7:52:11 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    ClearPoint Neuro Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

      B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $10.00

      7/25/24 8:27:37 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on ClearPoint Neuro with a new price target

      Stifel initiated coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $8.00

      10/24/23 6:18:03 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

      B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $14.00

      2/16/23 7:44:43 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

      B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $15.00

      4/5/22 7:16:19 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on ClearPoint Neuro with a new price target

      Lake Street initiated coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $32.00

      3/18/21 8:50:57 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • B. Riley resumed coverage on ClearPoint Neuro with a new price target

      B. Riley resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $38.00 from $23.00 previously

      2/22/21 8:34:45 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • B. Riley reiterated coverage on ClearPoint Neuro with a new price target

      B. Riley reiterated coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $23.00 from $18.00 previously

      1/24/21 2:54:32 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    ClearPoint Neuro Inc. SEC Filings

    See more
    • SEC Form DEF 14A filed by ClearPoint Neuro Inc.

      DEF 14A - ClearPoint Neuro, Inc. (0001285550) (Filer)

      4/9/25 4:22:15 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by ClearPoint Neuro Inc.

      10-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      2/26/25 5:17:38 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      2/26/25 4:05:29 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      11/7/24 5:02:26 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B5 filed by ClearPoint Neuro Inc.

      424B5 - ClearPoint Neuro, Inc. (0001285550) (Filer)

      11/7/24 5:00:42 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by ClearPoint Neuro Inc.

      10-Q - ClearPoint Neuro, Inc. (0001285550) (Filer)

      11/7/24 4:12:19 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      11/7/24 4:07:25 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      8/26/24 4:06:23 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by ClearPoint Neuro Inc.

      10-Q - ClearPoint Neuro, Inc. (0001285550) (Filer)

      8/7/24 5:16:29 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      8/7/24 4:05:59 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    ClearPoint Neuro Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/12/24 2:35:26 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/8/24 4:33:36 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/4/24 11:28:38 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by ClearPoint Neuro Inc.

      SC 13D/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      8/27/24 4:45:10 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by ClearPoint Neuro Inc.

      SC 13G - ClearPoint Neuro, Inc. (0001285550) (Subject)

      2/13/24 5:02:36 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ClearPoint Neuro Inc. (Amendment)

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      2/6/24 4:30:26 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by ClearPoint Neuro Inc. (Amendment)

      SC 13D/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      6/15/23 4:41:14 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ClearPoint Neuro Inc. (Amendment)

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      2/9/23 4:30:46 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ClearPoint Neuro Inc. (Amendment)

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      1/25/22 8:34:15 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by ClearPoint Neuro Inc.

      SC 13G - ClearPoint Neuro, Inc. (0001285550) (Subject)

      6/9/21 9:20:31 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    ClearPoint Neuro Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    ClearPoint Neuro Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    ClearPoint Neuro Inc. Financials

    Live finance-specific insights

    See more

    ClearPoint Neuro Inc. Leadership Updates

    Live Leadership Updates

    See more
    • ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

      Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United StatesSOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This signifies th

      11/13/24 1:20:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Reports Third Quarter 2024 Results

      Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024.Third Quarter HighlightsReported quarterly revenue of $8.1 million, a 41% year-over-year increase;Accelerated growth of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System, contributing to record navigation and device revenue of $2.9 million, a 53% year-over-year increase;Overall product revenue, inc

      11/7/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

      President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast TodaySOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence Vanguards of Healthcare Podcast series published today. The link to the interview published this morning on Bloomberg can be found HERE.Healthcare Conferences with Participation of ClearPoint Neuro Management Include:UBS Global Healthcare Conference in

      10/31/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

      SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 third quarter on Thursday, November 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or a

      10/17/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Announces Early Repayment of $10 Million Note

      SOLANA BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that on August 23, 2024, it provided for the full early repayment of the principal amount and interest on a $10 million convertible note held by PTC Therapeutics Inc., which would have matured in January 2025 according to its terms. The convertible note was issued by the Company pursuant to a financing transaction which was completed in January 2020. "PTC has been and continues to be a strong partner of ClearPoint Neuro. The early repayment of our convertibl

      8/26/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Reports Second Quarter 2024 Results

      SOLANA BEACH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 2024. Second Quarter Highlights Reported quarterly revenue of $7.9 million, a 32% year-over-year increase;Product revenue across all segments more than doubled, and grew 112% to $4.9 million;Increased Biologics and Drug Delivery revenue to $4.3 million, a 28% year-over-year increase;Full market release of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System contributing to record navigation and d

      8/7/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

      SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 second quarter on Wednesday, August 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or

      7/17/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial

      SOLANA BEACH, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner Aspen Neuroscience, Inc. on use of the ClearPoint Neuro Navigation System to transplant dopaminergic neuron precursor cells (DANPCs) for all enrolled patients with Parkinson's Disease (PD) in its recently launched ASPIRO Phase 1/2a clinical trial. ASPIRO is an open label trial to assess safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for participants with moderate to severe PD. The DANPCs

      6/20/24 8:45:00 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Parkinson's Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients' Own Autologous Replacement Neurons

      Aspen Neuroscience Announces MRI-Guided Transplantation Approach for ASPIRO Clinical Trial with the ClearPoint® Navigation System SAN DIEGO, June 20, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc. announced today that it is utilizing the MRI-guided ClearPoint® Navigation System for all patients enrolled in the recently launched ASPIRO Phase 1/2a clinical trial for transplantation of dopaminergic neuron precursor cells (DANPCs) in patients with Parkinson's Disease (PD). ASPIRO is an open label trial to assess safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for participants with moderate to severe PD.

      6/20/24 8:30:00 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System

      SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announces full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 Biennial Meeting of the American Society of Stereotactic and Functional Neurosurgery from Saturday, June 1st – Tuesday, June 4th in Nashville. "Deep Brain Stimulation (DBS) has been proven to be a safe and effective strategy to manage patients with medically intractable Parkinson's Disease, Essential Tremor, and Dystonia,1" said Dr. Kim Bur

      6/1/24 8:59:59 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

      For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

      11/14/24 8:50:18 AM ET
      $CLPT
      $PTCT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

      SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 third quarter on Thursday, November 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or a

      10/17/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

      SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 second quarter on Wednesday, August 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or

      7/17/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024

      SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 first quarter on Tuesday, May 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 first quarter on Tuesday, May 7th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201

      4/23/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024

      SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2023 fourth quarter and full year on Tuesday, March 12th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2023 fourth quarter and full year results on Tuesday, March 12th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telep

      3/1/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Reports Third Quarter 2023 Results

      SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2023. Third Quarter Highlights Reported quarterly revenue of $5.8 million, a 12% year-over-year increase;Increased biologics and drug delivery revenue to $3.5 million, a 55% year-over-year increase;Operational cash burn of $1.8 million, the lowest quarterly burn since 2020;Entered into new strategic biologics and drug delivery agreements, including additional milestone-based agreement;Submitted three new stereotacti

      11/9/23 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce Third Quarter 2023 Results November 9, 2023

      SOLANA BEACH, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2023 third quarter on Thursday, November 9, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2023 third quarter on Thursday, November 9, 2023, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (800) 715-9871, or at (646) 307-196

      10/26/23 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Reports Second Quarter 2023 Results

      SOLANA BEACH, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2023. Second Quarter Highlights Reported record quarterly revenue of $6.0 million, a 14% year-over-year increase;Increased biologics and drug delivery revenue to $3.4 million, a 40% year-over-year increase;Announced an example of a milestone-based biologics and drug delivery agreement whereby ClearPoint would earn cash compensation based on the successful progression of a drug candidate through the clinical and regulato

      8/8/23 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce Second Quarter 2023 Results August 8, 2023

      SOLANA BEACH, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2023 second quarter on Tuesday, August 8, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2023 second quarter on Tuesday, August 8, 2023, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 437-3179, or at (862) 298-0702 if

      7/25/23 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Reports First Quarter 2023 Results

      SOLANA BEACH, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2023. First Quarter Highlights Reported quarterly revenue of $5.4 million, a 8% year-over-year increase;Increased biologics and drug delivery revenue to $2.7 million, a 24% year-over-year increase;Announced exclusive multi-year licensing agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform;Added multiple new biologics and drug delivery partners in the quarter to bring the total to more than 50;Ins

      5/11/23 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023

      SOLANA BEACH, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2023 first quarter on Thursday, May 11, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2023 first quarter on Thursday, May 11, 2023, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or at (862) 298-0702 if ca

      4/28/23 4:42:12 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

      SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating Officer. Mr. Sabra will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to have Mazin join our team and bring his valuable and relevant skill set into our organization," commented Joe Burnett, President and CEO at ClearPoint Neuro. "Our pharma and device partners in many ways view ClearP

      9/20/22 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs

      SOLANA BEACH, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mary McNamara-Cullinane has joined the Company as Vice President of Regulatory Affairs. Ms. McNamara-Cullinane will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to welcome Mary to our team as we fully expect her leadership and experience in Regulatory Affairs will contribute immediately to our partners and to patients globally," commented Joe Burnett, Presiden

      8/8/22 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors

      SOLANA BEACH, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Company's Board of Directors effective immediately. Ms. Fallon will also become a member of the Company's Audit Committee. Ms. Fallon is the Executive Vice President, HR/Legal, General Counsel and Secretary of Axcelis Technologies, Inc. (NASDAQ:ACLS), a provider of equipment and service solutions for the semiconductor manufacturing industry, with locations in eight countries. Ms. Fallon has held her current position sin

      7/15/21 4:30:00 PM ET
      $CLPT
      $ACLS
      Medical/Dental Instruments
      Health Care
      Industrial Machinery/Components
      Technology
    • ClearPoint Neuro, Inc. Announces Retirement of Director John N. Spencer, Jr.

      SOLANA BEACH, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today the upcoming retirement of John N. Spencer, Jr. from its Board of Directors. Mr. Spencer, who has as served as a director since March 2010, is retiring when his current term of office expires effective at ClearPoint's Annual Meeting of Stockholders to be held on June 3, 2021. "Jack has contributed substantially to the growth of our Company and will be missed," commented Joe Burnett, President and CEO of ClearPoint Neuro. "He has been a steady force, helping to navigate this

      4/13/21 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel

      IRVINE, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ellisa Cholapranee will join the Company as General Counsel on April 5, 2021. Ms. Cholapranee will report directly to Joe Burnett, ClearPoint Neuro’s Chief Executive Officer, and serve as a member of the Company’s senior leadership team. “Ellisa is a tremendous addition to our capable and growing leadership team,” commented Joe Burnett, President and CEO of ClearPoint Neuro. “Not only does Ellisa offer the broad experience in compliance, contracting and strategy, but li

      3/24/21 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro, Inc. Announces Appointment of R. John Fletcher as Chairman of the Board of Directors

      IRVINE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that R. John Fletcher has been appointed Chairman of the Company’s Board of Directors. The prior Chairman, Kimble L. Jenkins, retired from the Chairman role, which he has held since 2003, and resigned from the Board of Directors to focus on commitments associated with his role as the Chief Executive Officer of OrthoSouth. “On behalf of our Board and the management team, we thank Kim for his service and longstanding commitment to the Company. We greatly appreciate the leadership, insight, and expertise that Kim has provided, taking us from a pre-regulatory, pre-revenue

      2/5/21 8:00:00 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care